Stay updated on IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial

Sign up to get notified when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision label in the page footer updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T14:56:38.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    The page now shows a new Revision: v3.4.2, and the previous funding-status notice and Revision: v3.4.1 have been removed.
    Difference
    0.2%
    Check dated 2026-02-11T06:17:01.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The history shows a site-wide funding notice and a new page revision to v3.4.1, replacing v3.4.0.
    Difference
    0.2%
    Check dated 2026-02-04T04:57:12.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a Show glossary toggle and clarified color-coded change indicators (green for additions, red for deletions) on the history page. Updated the revision label to v3.4.0, replacing the previous v3.3.4.
    Difference
    0.3%
    Check dated 2026-01-28T03:18:03.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    New site revision v3.3.4 appears in the history, indicating a minor update; no study data or page content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T01:34:39.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added Outcome Measures (Results), References, and Study Status, and updated revision to v3.3.3; removed HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.2%
    Check dated 2025-12-23T09:24:42.000Z thumbnail image

Stay in the know with updates to IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.